25 XP   0   0   10

Theravance Biopharma Inc
Buy, Hold or Sell?

Let's analyse Theravance together

PenkeI guess you are interested in Theravance Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Theravance Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Theravance Biopharma Inc

I send you an email if I find something interesting about Theravance Biopharma Inc.

Quick analysis of Theravance (30 sec.)










What can you expect buying and holding a share of Theravance? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€4.16
Expected worth in 1 year
€1.95
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
€-2.21
Return On Investment
-24.4%

For what price can you sell your share?

Current Price per Share
€9.05
Expected price per share
€7.6 - €9.4
How sure are you?
50%

1. Valuation of Theravance (5 min.)




Live pricePrice per Share (EOD)

€9.05

Intrinsic Value Per Share

€28.74 - €35.50

Total Value Per Share

€32.89 - €39.65

2. Growth of Theravance (5 min.)




Is Theravance growing?

Current yearPrevious yearGrowGrow %
How rich?$213m$55.2m$222.1m80.1%

How much money is Theravance making?

Current yearPrevious yearGrowGrow %
Making money-$13.7m$218m-$231.8m-1,680.1%
Net Profit Margin-107.8%1,755.1%--

How much money comes from the company's main activities?

3. Financial Health of Theravance (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#244 / 1019

Most Revenue
#267 / 1019

Most Profit
#617 / 1019

Most Efficient
#579 / 1019

What can you expect buying and holding a share of Theravance? (5 min.)

Welcome investor! Theravance's management wants to use your money to grow the business. In return you get a share of Theravance.

What can you expect buying and holding a share of Theravance?

First you should know what it really means to hold a share of Theravance. And how you can make/lose money.

Speculation

The Price per Share of Theravance is €9.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Theravance.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Theravance, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €4.16. Based on the TTM, the Book Value Change Per Share is €-0.55 per quarter. Based on the YOY, the Book Value Change Per Share is €2.67 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Theravance.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.18-2.0%-0.25-2.8%3.2836.2%0.010.1%-0.24-2.7%
Usd Book Value Change Per Share-0.42-4.7%-0.59-6.5%2.8431.4%0.273.0%0.182.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.42-4.7%-0.59-6.5%2.8431.4%0.273.0%0.182.0%
Usd Price Per Share10.85-9.87-9.90-13.90-15.76-
Price to Earnings Ratio-15.36--10.71--11.05--6.91--6.50-
Price-to-Total Gains Ratio-25.78--18.73--42.04--32.05--29.58-
Price to Book Ratio2.45-1.94--0.17--2.51--4.66-
Price-to-Total Gains Ratio-25.78--18.73--42.04--32.05--29.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.63101
Number of shares103
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.590.27
Usd Total Gains Per Share-0.590.27
Gains per Quarter (103 shares)-60.5428.29
Gains per Year (103 shares)-242.16113.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-242-2520113103
20-484-4940226216
30-726-7360339329
40-969-9780453442
50-1211-12200566555
60-1453-14620679668
70-1695-17040792781
80-1937-19460905894
90-2179-2188010181007
100-2422-2430011321120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.024.00.04.0%1.024.00.04.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%4.016.00.020.0%5.020.00.020.0%5.020.00.020.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.025.00.0%0.00.025.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%4.016.00.020.0%5.020.00.020.0%5.020.00.020.0%

Fundamentals of Theravance

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-03-27 12:16:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Theravance Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Theravance earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • A Net Profit Margin of -48.4% means that €-0.48 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Theravance Biopharma Inc:

  • The MRQ is -48.4%. The company is making a huge loss. -2
  • The TTM is -107.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-48.4%TTM-107.8%+59.4%
TTM-107.8%YOY1,755.1%-1,862.9%
TTM-107.8%5Y69.3%-177.1%
5Y69.3%10Y-91.1%+160.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.4%-196.9%+148.5%
TTM-107.8%-211.2%+103.4%
YOY1,755.1%-279.3%+2,034.4%
5Y69.3%-436.8%+506.1%
10Y-91.1%-599.3%+508.2%
1.1.2. Return on Assets

Shows how efficient Theravance is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • -2.2% Return on Assets means that Theravance generated €-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Theravance Biopharma Inc:

  • The MRQ is -2.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.2%TTM-3.0%+0.8%
TTM-3.0%YOY27.2%-30.2%
TTM-3.0%5Y-2.8%-0.2%
5Y-2.8%10Y-5.0%+2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.2%-13.6%+11.4%
TTM-3.0%-12.9%+9.9%
YOY27.2%-11.9%+39.1%
5Y-2.8%-14.2%+11.4%
10Y-5.0%-16.2%+11.2%
1.1.3. Return on Equity

Shows how efficient Theravance is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • -4.0% Return on Equity means Theravance generated €-0.04 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Theravance Biopharma Inc:

  • The MRQ is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM-4.8%+0.8%
TTM-4.8%YOY47.1%-51.9%
TTM-4.8%5Y8.5%-13.3%
5Y8.5%10Y-5.1%+13.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-17.0%+13.0%
TTM-4.8%-16.1%+11.3%
YOY47.1%-15.4%+62.5%
5Y8.5%-20.0%+28.5%
10Y-5.1%-21.1%+16.0%

1.2. Operating Efficiency of Theravance Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Theravance is operating .

  • Measures how much profit Theravance makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Theravance Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-83.2%+83.2%
TTM-83.2%YOY-158.8%+75.6%
TTM-83.2%5Y-306.3%+223.1%
5Y-306.3%10Y-390.8%+84.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--282.4%+282.4%
TTM-83.2%-225.8%+142.6%
YOY-158.8%-288.4%+129.6%
5Y-306.3%-475.2%+168.9%
10Y-390.8%-624.7%+233.9%
1.2.2. Operating Ratio

Measures how efficient Theravance is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.38 means that the operating costs are €1.38 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 1.376. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.065. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.376TTM2.065-0.690
TTM2.065YOY2.697-0.632
TTM2.0655Y4.408-2.343
5Y4.40810Y6.278-1.870
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3762.994-1.618
TTM2.0653.247-1.182
YOY2.6973.766-1.069
5Y4.4085.675-1.267
10Y6.2787.857-1.579

1.3. Liquidity of Theravance Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Theravance is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.39 means the company has €5.39 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 5.392. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.392. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.392TTM7.392-2.000
TTM7.392YOY6.321+1.072
TTM7.3925Y5.194+2.198
5Y5.19410Y5.079+0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3923.930+1.462
TTM7.3924.251+3.141
YOY6.3215.436+0.885
5Y5.1946.045-0.851
10Y5.0796.383-1.304
1.3.2. Quick Ratio

Measures if Theravance is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • A Quick Ratio of 3.24 means the company can pay off €3.24 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 3.244. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.013. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.244TTM3.013+0.231
TTM3.013YOY1.562+1.451
TTM3.0135Y2.215+0.798
5Y2.21510Y2.306-0.091
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2443.629-0.385
TTM3.0134.065-1.052
YOY1.5625.390-3.828
5Y2.2155.993-3.778
10Y2.3066.277-3.971

1.4. Solvency of Theravance Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Theravance assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Theravance to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.44 means that Theravance assets are financed with 44.2% credit (debt) and the remaining percentage (100% - 44.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 0.442. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.383. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.442TTM0.383+0.059
TTM0.383YOY1.150-0.767
TTM0.3835Y1.238-0.855
5Y1.23810Y1.177+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4420.332+0.110
TTM0.3830.333+0.050
YOY1.1500.268+0.882
5Y1.2380.366+0.872
10Y1.1770.390+0.787
1.4.2. Debt to Equity Ratio

Measures if Theravance is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • A Debt to Equity ratio of 79.3% means that company has €0.79 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 0.793. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.630. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.793TTM0.630+0.163
TTM0.630YOY0.241+0.389
TTM0.6305Y0.174+0.456
5Y0.17410Y0.966-0.791
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7930.380+0.413
TTM0.6300.389+0.241
YOY0.2410.334-0.093
5Y0.1740.432-0.258
10Y0.9660.465+0.501

2. Market Valuation of Theravance Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Theravance generates.

  • Above 15 is considered overpriced but always compare Theravance to the Biotechnology industry mean.
  • A PE ratio of -15.36 means the investor is paying €-15.36 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Theravance Biopharma Inc:

  • The EOD is -13.627. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.359. Based on the earnings, the company is expensive. -2
  • The TTM is -10.707. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.627MRQ-15.359+1.732
MRQ-15.359TTM-10.707-4.652
TTM-10.707YOY-11.053+0.346
TTM-10.7075Y-6.910-3.797
5Y-6.91010Y-6.498-0.413
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.627-2.426-11.201
MRQ-15.359-2.552-12.807
TTM-10.707-2.656-8.051
YOY-11.053-4.143-6.910
5Y-6.910-6.252-0.658
10Y-6.498-6.108-0.390
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Theravance Biopharma Inc:

  • The EOD is -75.745. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -85.370. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -37.651. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-75.745MRQ-85.370+9.625
MRQ-85.370TTM-37.651-47.719
TTM-37.651YOY-6.846-30.806
TTM-37.6515Y-10.609-27.042
5Y-10.60910Y-8.488-2.122
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-75.745-3.199-72.546
MRQ-85.370-3.259-82.111
TTM-37.651-3.552-34.099
YOY-6.846-5.617-1.229
5Y-10.609-8.326-2.283
10Y-8.488-8.689+0.201
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Theravance is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.45 means the investor is paying €2.45 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Theravance Biopharma Inc:

  • The EOD is 2.178. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.455. Based on the equity, the company is underpriced. +1
  • The TTM is 1.943. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.178MRQ2.455-0.277
MRQ2.455TTM1.943+0.511
TTM1.943YOY-0.175+2.118
TTM1.9435Y-2.509+4.452
5Y-2.50910Y-4.664+2.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1781.947+0.231
MRQ2.4552.116+0.339
TTM1.9432.095-0.152
YOY-0.1752.836-3.011
5Y-2.5093.443-5.952
10Y-4.6643.791-8.455
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Theravance Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.396-0.552+40%2.670-115%0.258-253%0.166-338%
Book Value Per Share--4.1564.840-14%1.121+271%-0.984+124%-0.672+116%
Current Ratio--5.3927.392-27%6.321-15%5.194+4%5.079+6%
Debt To Asset Ratio--0.4420.383+16%1.150-62%1.238-64%1.177-62%
Debt To Equity Ratio--0.7930.630+26%0.241+229%0.174+355%0.966-18%
Dividend Per Share----0%-0%-0%-0%
Eps---0.166-0.237+43%3.082-105%0.008-2080%-0.229+38%
Free Cash Flow Per Share---0.030-0.124+316%-0.652+2084%-0.608+1935%-0.608+1935%
Free Cash Flow To Equity Per Share---0.627-1.085+73%-0.909+45%-0.593-5%-0.593-5%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--35.495--------
Intrinsic Value_10Y_min--28.736--------
Intrinsic Value_1Y_max---1.179--------
Intrinsic Value_1Y_min---1.161--------
Intrinsic Value_3Y_max--0.066--------
Intrinsic Value_3Y_min---0.009--------
Intrinsic Value_5Y_max--5.664--------
Intrinsic Value_5Y_min--4.946--------
Market Cap435890535.000-13%491279940.000494876347.500-1%656335189.350-25%791681015.428-38%843136759.426-42%
Net Profit Margin---0.484-1.078+123%17.551-103%0.693-170%-0.911+88%
Operating Margin----0.8320%-1.5880%-3.0630%-3.9080%
Operating Ratio--1.3762.065-33%2.697-49%4.408-69%6.278-78%
Pb Ratio2.178-13%2.4551.943+26%-0.175+107%-2.509+202%-4.664+290%
Pe Ratio-13.627+11%-15.359-10.707-30%-11.053-28%-6.910-55%-6.498-58%
Price Per Share9.050-13%10.2009.275+10%9.300+10%13.063-22%14.806-31%
Price To Free Cash Flow Ratio-75.745+11%-85.370-37.651-56%-6.846-92%-10.609-88%-8.488-90%
Price To Total Gains Ratio-22.873+11%-25.780-18.731-27%-42.044+63%-32.053+24%-29.577+15%
Quick Ratio--3.2443.013+8%1.562+108%2.215+46%2.306+41%
Return On Assets---0.022-0.030+35%0.272-108%-0.028+27%-0.050+124%
Return On Equity---0.040-0.048+20%0.471-108%0.085-147%-0.051+28%
Total Gains Per Share---0.396-0.552+40%2.670-115%0.258-253%0.166-338%
Usd Book Value--213001121.476277469224.236-23%55281338.740+285%-79375931.199+137%-57583054.889+127%
Usd Book Value Change Per Share---0.421-0.588+40%2.842-115%0.275-253%0.177-338%
Usd Book Value Per Share--4.4225.151-14%1.193+271%-1.047+124%-0.715+116%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.177-0.252+43%3.280-105%0.009-2080%-0.244+38%
Usd Free Cash Flow---1531044.001-7371461.850+381%-46892097.640+2963%-34267534.821+2138%-27414027.857+1691%
Usd Free Cash Flow Per Share---0.032-0.132+316%-0.694+2084%-0.647+1935%-0.647+1935%
Usd Free Cash Flow To Equity Per Share---0.667-1.155+73%-0.967+45%-0.631-5%-0.631-5%
Usd Market Cap463874707.347-13%522820112.148526647409.010-1%698471908.506-25%842506936.618-38%897266139.381-42%
Usd Price Per Share9.631-13%10.8559.870+10%9.897+10%13.902-22%15.757-31%
Usd Profit---8510244.577-13798646.562+62%218038766.254-104%5152048.066-265%-7976549.239-6%
Usd Revenue--17565504.81814356412.591+22%12836868.921+37%15467994.537+14%14969870.222+17%
Usd Total Gains Per Share---0.421-0.588+40%2.842-115%0.275-253%0.177-338%
 EOD+3 -5MRQTTM+21 -11YOY+16 -165Y+16 -1610Y+21 -11

3.2. Fundamental Score

Let's check the fundamental score of Theravance Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.627
Price to Book Ratio (EOD)Between0-12.178
Net Profit Margin (MRQ)Greater than0-0.484
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.244
Current Ratio (MRQ)Greater than15.392
Debt to Asset Ratio (MRQ)Less than10.442
Debt to Equity Ratio (MRQ)Less than10.793
Return on Equity (MRQ)Greater than0.15-0.040
Return on Assets (MRQ)Greater than0.05-0.022
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Theravance Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose9.050
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets381,999
Total Liabilities169,004
Total Stockholder Equity212,995
 As reported
Total Liabilities 169,004
Total Stockholder Equity+ 212,995
Total Assets = 381,999

Assets

Total Assets381,999
Total Current Assets133,541
Long-term Assets248,458
Total Current Assets
Cash And Cash Equivalents 39,545
Short-term Investments 62,881
Net Receivables 17,474
Other Current Assets 11,603
Total Current Assets  (as reported)133,541
Total Current Assets  (calculated)131,503
+/- 2,038
Long-term Assets
Property Plant Equipment 45,355
Long-term Assets Other 203,103
Long-term Assets  (as reported)248,458
Long-term Assets  (calculated)248,458
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities24,767
Long-term Liabilities144,237
Total Stockholder Equity212,995
Total Current Liabilities
Accounts payable 1,524
Total Current Liabilities  (as reported)24,767
Total Current Liabilities  (calculated)1,524
+/- 23,243
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt49,159
Long-term Liabilities Other 33,707
Long-term Liabilities  (as reported)144,237
Long-term Liabilities  (calculated)82,866
+/- 61,371
Total Stockholder Equity
Total Stockholder Equity (as reported)212,995
Total Stockholder Equity (calculated)0
+/- 212,995
Other
Common Stock Shares Outstanding 48,091
Net Invested Capital 212,995
Net Working Capital 108,774
Property Plant and Equipment Gross 66,937



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
441,400
480,108
421,364
370,964
560,235
531,265
492,447
445,337
408,826
605,409
564,330
512,188
469,057
375,108
429,251
403,109
374,819
355,359
360,761
763,496
607,400
538,550
446,630
413,590
381,999
381,999413,590446,630538,550607,400763,496360,761355,359374,819403,109429,251375,108469,057512,188564,330605,409408,826445,337492,447531,265560,235370,964421,364480,108441,400
   > Total Current Assets 
378,749
446,818
386,693
332,606
532,823
467,233
426,038
355,652
338,488
534,218
498,386
450,724
393,341
293,071
333,180
297,172
249,870
204,636
154,729
511,718
353,464
261,338
192,003
161,690
133,541
133,541161,690192,003261,338353,464511,718154,729204,636249,870297,172333,180293,071393,341450,724498,386534,218338,488355,652426,038467,233532,823332,606386,693446,818378,749
       Cash And Cash Equivalents 
88,980
125,831
103,854
101,202
378,021
223,235
178,311
102,403
58,064
332,798
104,735
93,282
81,467
114,011
204,949
121,424
89,959
94,367
87,292
418,538
298,172
187,665
105,596
71,685
39,545
39,54571,685105,596187,665298,172418,53887,29294,36789,959121,424204,949114,01181,46793,282104,735332,79858,064102,403178,311223,235378,021101,202103,854125,83188,980
       Short-term Investments 
259,586
292,700
249,049
199,207
127,255
210,823
217,761
217,278
222,767
154,233
333,605
265,065
211,474
95,957
60,004
94,789
83,506
53,149
45,558
68,294
29,312
53,598
61,855
62,318
62,881
62,88162,31861,85553,59829,31268,29445,55853,14983,50694,78960,00495,957211,474265,065333,605154,233222,767217,278217,761210,823127,255199,207249,049292,700259,586
       Net Receivables 
9,362
4,818
7,299
6,931
16,073
7,937
1,090
4,682
21,996
15,414
11,413
12,399
69,667
54,274
39,961
57,774
57,599
47,836
12,488
14,114
16,785
12,270
15,796
17,057
17,474
17,47417,05715,79612,27016,78514,11412,48847,83657,59957,77439,96154,27469,66712,39911,41315,41421,9964,6821,0907,93716,0736,9317,2994,8189,362
       Inventory 
16,830
17,217
17,906
17,923
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000017,92317,90617,21716,830
   > Long-term Assets 
0
0
0
0
0
64,032
66,409
89,685
70,338
71,191
65,944
61,464
75,716
82,037
96,071
105,937
124,949
150,723
206,032
251,778
253,936
277,212
254,627
251,900
248,458
248,458251,900254,627277,212253,936251,778206,032150,723124,949105,93796,07182,03775,71661,46465,94471,19170,33889,68566,40964,03200000
       Property Plant Equipment 
10,157
10,329
10,677
12,415
13,176
61,760
60,493
58,944
59,248
60,011
59,617
59,821
59,682
59,461
58,091
56,721
53,347
52,585
53,643
51,876
52,001
51,307
48,006
46,864
45,355
45,35546,86448,00651,30752,00151,87653,64352,58553,34756,72158,09159,46159,68259,82159,61760,01159,24858,94460,49361,76013,17612,41510,67710,32910,157
       Long Term Investments 
41,587
16,999
18,252
20,217
11,869
0
0
24,939
4,985
5,067
0
0
12,750
19,439
35,822
45,086
67,537
94,108
148,250
0
0
18,776
0
0
0
00018,77600148,25094,10867,53745,08635,82219,43912,750005,0674,98524,9390011,86920,21718,25216,99941,587
       Long-term Assets Other 
0
0
0
0
0
2,272
2,221
2,138
2,423
2,141
2,341
1,643
3,284
3,137
2,158
4,130
4,065
4,030
4,139
199,902
201,935
207,129
206,621
205,036
203,103
203,103205,036206,621207,129201,935199,9024,1394,0304,0654,1302,1583,1373,2841,6432,3412,1412,4232,1382,2212,27200000
> Total Liabilities 
326,222
416,701
386,977
384,409
611,824
644,517
629,671
628,142
632,666
763,345
766,666
773,724
772,808
748,326
729,625
726,701
713,392
706,809
710,570
282,918
165,600
167,991
166,469
167,460
169,004
169,004167,460166,469167,991165,600282,918710,570706,809713,392726,701729,625748,326772,808773,724766,666763,345632,666628,142629,671644,517611,824384,409386,977416,701326,222
   > Total Current Liabilities 
62,552
105,179
93,480
102,029
98,554
113,542
110,136
108,823
111,703
98,040
106,574
104,270
123,571
86,492
67,127
66,082
58,587
44,201
32,624
142,132
28,715
26,184
24,546
25,368
24,767
24,76725,36824,54626,18428,715142,13232,62444,20158,58766,08267,12786,492123,571104,270106,57498,040111,703108,823110,136113,54298,554102,02993,480105,17962,552
       Short-term Debt 
0
0
0
0
0
8,300
12,348
8,701
9,851
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000009,8518,70112,3488,30000000
       Short Long Term Debt 
0
0
0
0
0
8,300
12,348
8,701
9,851
0
0
0
19,334
11,659
6,941
12,530
16,940
9,012
0
0
0
0
0
0
0
00000009,01216,94012,5306,94111,65919,3340009,8518,70112,3488,30000000
       Accounts payable 
5,924
5,085
3,644
3,745
9,028
5,596
3,501
8,713
4,758
6,645
10,065
6,442
6,775
6,834
10,702
8,900
3,098
1,510
3,074
5,337
1,554
2,663
1,569
2,368
1,524
1,5242,3681,5692,6631,5545,3373,0741,5103,0988,90010,7026,8346,7756,44210,0656,6454,7588,7133,5015,5969,0283,7453,6445,0855,924
       Other Current Liabilities 
125
50,162
54,478
57,239
43,402
15,587
6,432
6,549
31,575
23,193
25,062
18,204
11,523
7,661
5,690
2,902
98
98
24
120,574
24
26,184
24
0
0
002426,18424120,5742498982,9025,6907,66111,52318,20425,06223,19331,5756,5496,43215,58743,40257,23954,47850,162125
   > Long-term Liabilities 
0
0
0
0
0
530,975
519,535
519,319
520,963
665,305
660,092
669,454
649,237
661,834
662,498
660,619
654,805
662,608
677,946
140,786
136,885
141,807
141,923
142,092
144,237
144,237142,092141,923141,807136,885140,786677,946662,608654,805660,619662,498661,834649,237669,454660,092665,305520,963519,319519,535530,97500000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
40,193
44,104
46,752
45,636
55,153
56,372
57,508
47,220
57,026
57,768
54,353
52,681
51,469
50,642
51,381
74,122
43,763
42,521
50,831
49,159
49,15950,83142,52143,76374,12251,38150,64251,46952,68154,35357,76857,02647,22057,50856,37255,15345,63646,75244,10440,19300000
       Long-term Liabilities Other 
0
0
0
0
0
14,261
14,457
8,900
21,287
9,583
9,614
9,704
2,181
2,397
2,162
2,929
2,730
2,428
2,608
89,405
91,478
98,044
99,402
34,844
33,707
33,70734,84499,40298,04491,47889,4052,6082,4282,7302,9292,1622,3972,1819,7049,6149,58321,2878,90014,45714,26100000
> Total Stockholder Equity
115,178
63,407
34,387
-13,445
-51,589
-113,252
-137,224
-182,805
-223,840
-157,936
-202,336
-261,536
-303,751
-373,218
-300,374
-323,592
-338,573
-351,450
-349,809
480,578
441,800
370,559
280,161
246,130
212,995
212,995246,130280,161370,559441,800480,578-349,809-351,450-338,573-323,592-300,374-373,218-303,751-261,536-202,336-157,936-223,840-182,805-137,224-113,252-51,589-13,44534,38763,407115,178
   Common Stock
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
370,559
1
0
0
001370,559111111111111111111111
   Retained Earnings Total Equity0000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
-733
-854
-525
-331
-166
-36
129
94
145
512
280
122
47
17
8
14
0
-28
-45
-121
-15
0
-286
0
0
00-2860-15-121-45-280148174712228051214594129-36-166-331-525-854-733



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue57,424
Cost of Revenue--
Gross Profit-57,424
 
Operating Income (+$)
Gross Profit-
Operating Expense-111,073
Operating Income-53,649-111,073
 
Operating Expense (+$)
Research Development40,621
Selling General Administrative70,452
Selling And Marketing Expenses-
Operating Expense111,073111,073
 
Net Interest Income (+$)
Interest Income9,116
Interest Expense-2,350
Other Finance Cost-0
Net Interest Income6,766
 
Pretax Income (+$)
Operating Income-53,649
Net Interest Income6,766
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-49,269-51,263
EBIT - interestExpense = -2,350
-55,193
-52,843
Interest Expense2,350
Earnings Before Interest and Taxes (EBIT)--46,919
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-49,269
Tax Provision-5,924
Net Income From Continuing Ops-55,193-55,193
Net Income-55,193
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-2,386-6,766
 

Technical Analysis of Theravance
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Theravance. The general trend of Theravance is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Theravance's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Theravance Biopharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.95 < 9.25 < 9.4.

The bearish price targets are: 7.75 > 7.6.

Tweet this
Theravance Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Theravance Biopharma Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Theravance Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartTheravance Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Theravance Biopharma Inc. The current adx is .

Theravance Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Relative Strength Index (RSI) ChartTheravance Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Stochastic Oscillator ChartTheravance Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Commodity Channel Index (CCI) ChartTheravance Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartTheravance Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Williams %R ChartTheravance Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Average True Range (ATR) ChartTheravance Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily On-Balance Volume (OBV) ChartTheravance Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Money Flow Index (MFI) ChartTheravance Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Theravance Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-08 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-14 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Theravance Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Theravance Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose9.050
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Theravance with someone you think should read this too:
  • Are you bullish or bearish on Theravance? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Theravance? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Theravance Biopharma Inc

I send you an email if I find something interesting about Theravance Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Theravance Biopharma Inc.

Receive notifications about Theravance Biopharma Inc in your mailbox!